Combination of the anti-CD30-auristatin-E antibody-drug conjugate (SGN-35) with chemotherapy improves antitumour activity in Hodgkin lymphoma

被引：93

作者：

Oflazoglu, Ezogelin ^{[1
]}

Kissler, Kim M. ^{[1
]}

Sievers, Eric L. ^{[2
]}

Grewal, Iqbal S. ^{[1
]}

Gerber, Hans-Peter ^{[1
]}

机构：

[1] Seattle Genet Inc, Dept Preclin Therapeut, Bothell, WA 98021 USA

[2] Seattle Genet Inc, Dept Clin, Bothell, WA 98021 USA

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2008年 / 142卷 / 01期

关键词：

SGN-35; antibody-drug conjugate; ABVD; gemcitabine; Hodgkin lymphoma;

D O I：

10.1111/j.1365-2141.2008.07146.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The antibody-drug conjugate (ADC) cAC10-vcMMAE consists of the tubulin inhibitor monomethyl auristatin E (MMAE) conjugated to the chimeric anti-CD30 monoclonal antibody cAC10. This ADC potently interferes with the growth of CD30-positive haematological tumours, including Hodgkin lymphoma (HL) and anaplastic large-cell lymphoma. This study found improved antitumour activity in a preclinical model of HL when SGN-35 was combined with chemotherapeutic regimens such as ABVD (doxorubicin, bleomycin, vinblastine and dacarbazine) or gemcitabine. Improved efficacy was also observed in high tumour burden models, indicating that combining ADCs with chemotherapeutic agents may be advantageous for the treatment of patients with relapsed or refractory HL.

引用

页码：69 / 73

页数：5

共 13 条

[1]

Bai M, 2005, IN VIVO, V19, P439

[2] Salvage therapy in Hodgkin's lymphoma [J].

Byrne, Brian J. ;

Gockerman, Jon P. .

ONCOLOGIST, 2007, 12 (02) :156-167

[3]

CHABNE BA, 2001, WILLIAMS HEMATOLOGY, P193

[4] Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: Report of an intergroup trial [J].

Duggan, DB ;

Petroni, GR ;

Johnson, JL ;

Glick, JH ;

Fisher, RI ;

Connors, JM ;

Canellos, GP ;

Peterson, BA .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (04) :607-614

[5] cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity [J].

Francisco, JA ;

Cerveny, CG ;

Meyer, DL ;

Mixan, BJ ;

Klussman, K ;

Chace, DF ;

Rejniak, SX ;

Gordon, KA ;

DeBlanc, R ;

Toki, BE ;

Law, CL ;

Doronina, SO ;

Siegall, CB ;

Senter, PD ;

Wahl, AF .

BLOOD, 2003, 102 (04) :1458-1465

[6] Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate [J].

Hamblett, KJ ;

Senter, PD ;

Chace, DF ;

Sun, MMC ;

Lenox, J ;

Cerveny, CG ;

Kissler, KM ;

Bernhardt, SX ;

Kopcha, AK ;

Zabinski, RF ;

Meyer, DL ;

Francisco, JA .

CLINICAL CANCER RESEARCH, 2004, 10 (20) :7063-7070

[7]

Klimm B, 2005, HAEMATOLOGICA, V90, P1680

[8] The origin of Hodgkin and Reed/Sternberg cells in Hodgkin's disease [J].

Küppers, R ;

Rajewsky, K .

ANNUAL REVIEW OF IMMUNOLOGY, 1998, 16 :471-493

[9] Gemcitabine in the treatment of refractory Hodgkins's disease: Results of a multicenter phase II study [J].

Santoro, A ;

Bredenfeld, H ;

Devizzi, L ;

Tesch, H ;

Bonfante, V ;

Viviani, S ;

Fielder, F ;

Parra, HS ;

Benoehr, C ;

Pacini, M ;

Bonadonna, G ;

Diehl, V .

JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (13) :2615-2619

[10]

Schnell R, 2006, CURR OPIN MOL THER, V8, P164

← 1 2 →